Modality
mAb
MOA
VEGFi
Target
FXIa
Pathway
NF-κB
AngelmanSMAIPF
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Nov 2027
Phase 1Current
NCT06096462
2,719 pts·IPF
2025-12→2027-09·Recruiting
NCT04692250
933 pts·Angelman
2021-07→2027-11·Active
3,652 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-06-132mo awayBTD· IPF
2027-09-051.4y awayPh2 Data· IPF
2027-11-061.6y awayPh2 Data· Angelman
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Active
P1/2
Recruit…
Catalysts
BTD
2026-06-13 · 2mo away
IPF
Ph2 Data
2027-09-05 · 1.4y away
IPF
Ph2 Data
2027-11-06 · 1.6y away
Angelman
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06096462 | Phase 1/2 | IPF | Recruiting | 2719 | EASI-75 |
| NCT04692250 | Phase 1/2 | Angelman | Active | 933 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |